Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6

BACKGROUND: Tocilizumab (TCZ), an interleukin-6 receptor antibody, has previously been used for treating patients with the coronavirus disease 2019 (COVID-19), but there is a lack of data regarding the administration timing of TCZ. OBJECTIVES: This study aimed to evaluate the timing and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Pan, Lu, Zhengmao, Li, Qiang, Wang, Zhenmeng, Guo, Yan, Cai, Chen, Wang, Shengyun, Liu, Peng, Su, Xiaoping, Huang, Yi, Dong, Yuchao, Qiu, Wenjuan, Ling, Yueming, Yarmus, Lonny, Luo, Fengming, Zeng, Li, Bai, Chong, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084410/
https://www.ncbi.nlm.nih.gov/pubmed/33937333
http://dx.doi.org/10.3389/fmolb.2021.651662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084410/
https://www.ncbi.nlm.nih.gov/pubmed/33937333
http://dx.doi.org/10.3389/fmolb.2021.651662

Ejemplares similares